Open-Label Treatment Extension Study
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 208
- Registration Number
- NCT02896296
- Locations
- 🇺🇸
Boyett Health Services, Hamilton, Alabama, United States
🇺🇸Collaborative Neuroscience Network, Long Beach, California, United States
🇺🇸Meridien Research, Lakeland, Florida, United States
Single Ascending Dose Study of RBP-7000
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02768649
- Locations
- 🇺🇸
CRI Worldwide, Willingboro, New Jersey, United States
Single-dose, Study of RBP-6000 in Opioid Dependent Individuals
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02765867
- Locations
- 🇺🇸
Scientific Clinical Research, Ft. Lauderdale, Florida, United States
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02765555
- Locations
- 🇺🇸
CRI Worldwide, Willingboro, New Jersey, United States
PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02687984
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Garden Grove, California, United States
🇺🇸Collaborative Neuroscience Network, Torrance, California, United States
Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02559973
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02511886
- Locations
- 🇺🇸
Research Centers of America, Oakland Park, Florida, United States
Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 775
- Registration Number
- NCT02510014
- Locations
- 🇺🇸
Haleyville Clinical Research, Haleyville, Alabama, United States
🇺🇸Boyett Health Services, Hamilton, Alabama, United States
🇺🇸Collaborative Neuroscience Network, Garden Grove, California, United States
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
- Conditions
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 665
- Registration Number
- NCT02357901
- Locations
- 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸Louisiana Clinical Research, Shreveport, Louisiana, United States
🇺🇸Stanley Street Treatment and Resources, Fall River, Massachusetts, United States
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT02203838
- Locations
- 🇺🇸
CRI Lifetree - Philadelphia Unit, Philadelphia, Pennsylvania, United States
🇺🇸Behavioral Medical Research of Brooklyn, Brooklyn, New York, United States
🇺🇸Neurobehavioral Research, Cedarhurst, New York, United States